Shockwave

Shockwave Medical to Present at the Canaccord Genuity 41st Annual Growth Conference

Retrieved on: 
Wednesday, July 28, 2021
Genuity, Lithotripsy, Shockwave, Military personnel, Fictional characters, Military

SANTA CLARA, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 41st Annual Growth Conference, scheduled to be held virtually August 10 to 12, 2021.

Key Points: 
  • SANTA CLARA, Calif., July 28, 2021 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 41st Annual Growth Conference, scheduled to be held virtually August 10 to 12, 2021.
  • Shockwave's management is scheduled for a live fireside chat on Wednesday, August 11, 2021, at 11:30 a.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the event on the "Investors" section of the companys website at https://ir.shockwavemedical.com .
  • Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Shockwave Medical Reports First Quarter 2021 Financial Results

Retrieved on: 
Monday, May 10, 2021
Medical specialties, Clinical medicine, Medicine, Vascular diseases, Lithotripsy, Shockwave, Atherosclerosis, Coronary artery disease, Batman The Escape

The growth was primarily driven by the launch of the coronary product, Shockwave C2, in the U.S. in February and increased adoption of Shockwave products.\nGross profit for the first quarter of 2021 was $24.0 million compared to $9.5 million for the first quarter of 2020.

Key Points: 
  • The growth was primarily driven by the launch of the coronary product, Shockwave C2, in the U.S. in February and increased adoption of Shockwave products.\nGross profit for the first quarter of 2021 was $24.0 million compared to $9.5 million for the first quarter of 2020.
  • Gross margin for the first quarter of 2021 was 75%, as compared to 63% in the first quarter of 2020.
  • Net loss per share for the period was $0.68.\nCash, cash equivalents and short-term investments totaled $177.4 million as of March 31, 2021.\nShockwave Medical projects revenue for the full year 2021 to range from $195 million to $205 million, which would represent 188% to 202% growth over the company\xe2\x80\x99s prior year revenue.\nShockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, May 10, 2021 to discuss its first quarter 2021 financial results.
  • Shockwave Medical aims to establish a new standard of care for the interventional treatment of atherosclerotic cardiovascular disease through differentiated and proprietary local delivery of sonic pressure waves for the treatment of calcified plaque, which Shockwave Medical refers to as Intravascular Lithotripsy (IVL).

Shockwave Appoints Sara Toyloy to Board of Directors

Retrieved on: 
Thursday, March 25, 2021
Amusement rides, Amusement parks, Godshall, Shockwave, Batman The Escape, Six Flags

I am delighted to welcome Sara to our Board of Directors, said Doug Godshall, President and Chief Executive Officer of Shockwave Medical.

Key Points: 
  • I am delighted to welcome Sara to our Board of Directors, said Doug Godshall, President and Chief Executive Officer of Shockwave Medical.
  • Her background and depth of experience in regulatory and clinical affairs within the medical technology sector are a perfect complement to our current Directors.
  • Sara will be an invaluable resource and addition to Shockwave as we continue to build our business and increase access to IVL for patients across the globe.
  • I am honored and excited to join the Shockwave Medical Board of Directors, said Ms. Toyloy.

Shockwave Announces Joint Venture in China

Retrieved on: 
Monday, March 22, 2021
Fictional characters, Genesis, Shockwave, IVL, Military personnel, Military

Together, Shockwave and Genesis strive to bring coronary and peripheral IVL products to patients in mainland China.

Key Points: 
  • Together, Shockwave and Genesis strive to bring coronary and peripheral IVL products to patients in mainland China.
  • The joint venture will benefit from Genesis MedTechs strong track record and expertise in the commercialization of medical devices as well as their industry-leading sales network in China.
  • Genesis MedTech's China capabilities are complementary to Shockwave's global expertise in the development, manufacture, and sale of IVL products.
  • The new joint venture will be named Genesis Shockwave Private Limited and enables the commercialization of both imported Shockwave-branded IVL products as well as IVL products that are locally developed, manufactured, and branded by Genesis Shockwave Private Limited.

Global Shockwave Therapy Markets 2021-2025 - Shockwave Therapy Function / Conditions Effectively Treated with Shockwave Therapy / Benefits of Shockwave Therapy Treatment

Retrieved on: 
Friday, March 12, 2021
Health sciences, Amusement rides, Amusement parks, Shockwave, Batman The Escape, Therapy

DUBLIN, March 12, 2021 /PRNewswire/ -- The "Shockwave Therapy: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, March 12, 2021 /PRNewswire/ -- The "Shockwave Therapy: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • Drivers, restraints, opportunities, the impact of COVID-19, other applications of shockwave therapy and a regulatory scenario assessment will be covered in the current report.
  • This is likely to propel the growth of the shockwave therapy market during the forecast period.
  • Few shockwave therapy devices are approved by FDA, but significant testing has been performed, and much peer-reviewed research proves shockwave therapy to be effective in 80% of erectile dysfunction patients.

Global Shockwave Therapy Markets Report 2021: 2018-2020 Data and Projections through 2025 - Focus on Newer Shockwave Devices and Innovations in Frequency Length - ResearchAndMarkets.com

Retrieved on: 
Wednesday, March 10, 2021
Biotechnology, Health, Medical devices, Six Flags Great America, Six Flags, Amusement rides, Amusement parks, Batman The Escape, Batman in amusement parks, Six Flags AstroWorld, Six Flags Great Adventure, Six Flags Magic Mountain, Shockwave, Food and Drug Administration

The "Shockwave Therapy: Global Markets" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Shockwave Therapy: Global Markets" report has been added to ResearchAndMarkets.com's offering.
  • The report focuses on newer shockwave devices and innovations in frequency length, as well as devices that have been recently launched or are in development.
  • Drivers, restraints, opportunities, the impact of COVID-19, other applications of shockwave therapy and a regulatory scenario assessment will be covered in the current report.
  • Few shockwave therapy devices are approved by FDA, but significant testing has been performed, and much peer-reviewed research proves shockwave therapy to be effective in 80% of erectile dysfunction patients.

Shockwave Medical to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference

Retrieved on: 
Wednesday, November 18, 2020
Lithotripsy, Shockwave, Cardiovascular disease, Fictional characters, Military personnel

SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020.

Key Points: 
  • SANTA CLARA, Calif., Nov. 18, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Piper Sandler 32nd Annual Virtual Healthcare Conference, scheduled to be held December 1 to 3, 2020.
  • Shockwave's management is scheduled for a live fireside chat on Wednesday, December 2, 2020, at 8:30 a.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the event on the "Investors" section of the companys website at https://ir.shockwavemedical.com .
  • Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

Shockwave Medical Reports Third Quarter 2020 Financial Results

Retrieved on: 
Monday, November 9, 2020
Shockwave, Trucks

Revenue for the third quarter of 2020 was $19.6 million, an increase of $8.3 million, or 73%, compared to the third quarter of 2019.

Key Points: 
  • Revenue for the third quarter of 2020 was $19.6 million, an increase of $8.3 million, or 73%, compared to the third quarter of 2019.
  • Gross profit for the third quarter of 2020 was $14.3 million compared to $6.9 million for the third quarter of 2019.
  • As such, Shockwave is unable to estimate the pandemics impact on operations and financial results and is not issuing 2020 financial guidance at this time.
  • Shockwave Medical will host a conference call at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time on Monday, November 9, 2020 to discuss its third quarter 2020 financial results.

Shockwave Medical to Present at the Canaccord Genuity 40th Annual Growth Conference

Retrieved on: 
Thursday, July 30, 2020
Genuity, RTT, Lithotripsy, Cardiovascular disease, Shockwave, Military personnel, Fictional characters, Military

SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11 to 13, 2020.

Key Points: 
  • SANTA CLARA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the development of Intravascular Lithotripsy (IVL) to treat complex calcified cardiovascular disease, announced today that it will be participating in the Canaccord Genuity 40th Annual Growth Conference, scheduled to be held virtually August 11 to 13, 2020.
  • Shockwave's management is scheduled for a live fireside chat on Wednesday, August 12, 2020, at 2:30 p.m. Eastern Time.
  • Interested parties may access a live and archived webcast of the event on the "Investors" section of the companys website at https://ir.shockwavemedical.com .
  • Shockwave Medical is focused on developing and commercializing products intended to transform the way calcified cardiovascular disease is treated.

SANUWAVE Health Enters Into Exclusive Letter of Intent to Acquire Celularity’s UltraMIST® and Exclusive Partnership Rights for Wound Care Biologic Products

Retrieved on: 
Wednesday, June 10, 2020
Health sciences, Health, Articles, Drug discovery, Health policy, Medicinal chemistry, Therapy, Wound, Shockwave

SUWANEE, GA, June 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc.(OTCQB: SNWV)today announced that it has entered into an exclusive, non-binding letter of intent to acquire Celularitys UltraMIST Ultrasound Healing Therapy asset as well as exclusive partnership rights for Celularitys wound care biologic products.

Key Points: 
  • SUWANEE, GA, June 10, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- SANUWAVE Health, Inc.(OTCQB: SNWV)today announced that it has entered into an exclusive, non-binding letter of intent to acquire Celularitys UltraMIST Ultrasound Healing Therapy asset as well as exclusive partnership rights for Celularitys wound care biologic products.
  • UltraMISTand the Celularity wound care biologic products, Biovance and Interyl, are excellent complements to our dermaPACE System, said Kevin Richardson, SANUWAVE Chief Executive Officer.
  • We are excited about the prospect to bring Celularitys wound care technologies and 25 dedicated wound care professionals to our team, Mr. Richardson continued.
  • Together, we will apply shockwave and ultrasound science to bring differentiated offerings to key wound care solutions worldwide.